# A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV

> **NCT06905275** · PHASE1 · SUSPENDED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 25 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **BIOLOGICAL:** 3M-052-AF + Alum
- **BIOLOGICAL:** UVAX-1107
- **BIOLOGICAL:** UVAX-1197

## Key facts

- **NCT ID:** NCT06905275
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-07-07
- **Primary completion:** 2027-07-20
- **Final completion:** 2027-07-20
- **Target enrollment:** 25 (ESTIMATED)
- **Why stopped:** Temporarily Closed (Paused) to Accrual
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06905275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06905275, "A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06905275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*